ERYP
NASDAQ

Erytech Pharma SA ADR

Overview
ERYP
Symbol
NASDAQ
Exchange
About stock

ERYTECH Pharma S. A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.

The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-"-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France. Address: 60 Avenue Rockefeller, Lyon, France, 69008

Erytech Pharma SA ADR dividend calculator
Report issue